Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.58 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NGFR | P08138 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420703 | 0.79 | LMNA (0.62) | ARPARP1TNKS2CA12CA9 | |
| SCHEMBL8210948 | 0.78 | LMNA (0.56) | ARTNKS2CA12CA9LMNA | |
| SCHEMBL20838314 | 0.78 | AR (0.51) | ARLMNARPS6KA3PDPK1MEN1 | |
| SCHEMBL20680204 | 0.78 | AR (0.51) | ARTNKS2CA12CA9LMNA | |
| SCHEMBL1771631 | 0.78 | KDM4E (0.59) | ARPARP1PDE10ACA12CA9 | |
| SCHEMBL4148535 | 0.77 | AR (0.48) | ARLMNAPDPK1MEN1KMT2A | |
| SCHEMBL1770840 | 0.75 | AR (0.55) | ARPARP1PDE10ATNKS2CA12 | |
| SCHEMBL8369447 | 0.75 | AR (0.51) | ARPARP1PDE10ATNKS2CA12 | |
| SCHEMBL31169726 | 0.75 | CYP1A2 (0.62) | ARPARP1PDE10ATNKS2CA12 | |
| SCHEMBL2084671 | 0.75 | CYP1A2 (0.62) | ARPARP1PDE10ATNKS2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | claimed |
| JP-2003508387-A | — | — | 2003-03-04 | — | — | JP | claimed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | claimed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | claimed |
| CN-106573915-B | Compounds active against bromodomains | 纽韦卢森公司 | 2020-12-25 | — | — | CN | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016316-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2016-02-04 | — | — | WO | disclosed |
| EP-1891067-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8580811-B2 | Androgen receptor modulator methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| CN-1775759-A | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2006-05-24 | — | — | CN | disclosed |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | LIGAND PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | FSHR, CYP19A1, ESR2 | AR 9/4885PARP1 2730/4885PDE10A 1801/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | AR 904/4885PARP1 50/4885PDE10A 3536/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | AR 904/4885PARP1 50/4885PDE10A 3536/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | AR 1/4885PARP1 1903/4885PDE10A 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.